Improving first-line therapy of advanced ovarian cancer - The AGO Ovarian Cancer Study Group perspective

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 169-171

  Du Bois, Andres ^a,b   Pfisterer, J ^a   Meier, W ^a   Wagner, U ^a  

^a Dr Horst Schmidt Kliniken ^*

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL TRANSDUCTION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PACLITAXEL; RESEARCH DESIGN; TOPOTECAN;

EID: 1242342764     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.t01-2-13352.x     Document Type: Conference Paper

References (9)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
2. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advance eüpithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003 Sep 3;95(17):1320-29.
4. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-3200.
5. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10:S87-92.
6. Bauknecht T, Breitbach GP, du Bois A et al. Maligne ovarialtumoren. In: Deutsche Krebsgesellschaft e. V., Qualitätssicherung in der Onkologie, kurzgefasste Interdisziplinäre Leitlinien: Zuckschwerdt Verlag München, 2000.
7. du Bois A, Lück HJ, Bauknecht T et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin (ET-CARBO) for advanced ovarian cancer. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. J Clin Oncol 1999;17:46-51.
8. du Bois A, Weber B, Pfisterer J et al. Epirubicin/paclitaxel/ carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Interim results of an AGO-GINECO intergroup phase III trial. Proc Am Soc Clin Oncol 2001;20:202a [Abstract 805].
9. Kristensen G, Vergote I, Stuart G et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/ epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim analysis of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 2002;21:202a [Abstract 805].